Prolacta Bioscience Celebrates Nearly 20 Years of Advancements in Infant Nutrition for Premature Babies
Prolacta Bioscience® is a pioneering healthcare company recognized as the world's leading provider of human milk-based nutritional products aimed at critically ill and premature infants. As the sole source of 100% human milk fortifiers in U.S. hospitals, Prolacta has been instrumental in transforming neonatal care for nearly 20 years. Founded with a commitment to addressing the specific nutritional needs of vulnerable infants, the organization introduced its flagship product, Prolact+ H2MF®, in 2006. This groundbreaking fortifier was designed to replace traditional cow milk-based alternatives that studies have shown can increase the risk of serious conditions such as necrotizing enterocolitis (NEC).
The importance of this transition cannot be overstated, especially considering that multiple peer-reviewed studies over the years have confirmed the health risks associated with cow milk for infants born at a very low birth weight. For instance, research indicates that for every 10% increase in cow milk protein in an infant's diet, the risk of developing NEC rises substantially, alongside heightened susceptibility to surgical complications and sepsis.
In light of these findings, the introduction of Prolacta's human milk fortifiers has not only been a critical alternative in clinical settings but has also directly contributed to improving health outcomes for infants in neonatal intensive care units (NICUs). Prolacta's products contain 100% breast milk, are free from cow milk, added fats, and sugars, including corn syrup solids, which aids in reducing complications associated with traditional feeding methods.
Scott Elster, CEO of Prolacta, remarked on the company's extensive history and its enduring mission, stating, "Our legacy and continued mission reflect the vital role of human milk nutrition in helping extremely premature infants not just survive their earliest days but also grow and develop so they can thrive throughout their lives."
Notably, Prolacta's advancements in neonatal nutrition have led to several significant milestones over the years, including:
Prolacta's commitment to clinical efficacy has garnered substantial evidence favoring the nutritional superiority of its products. Studies consistently show that an exclusive human milk diet significantly lowers mortality rates, reduces the incidence of NEC, minimizes feeding intolerance, and improves overall growth, thereby leading to shorter NICU stays and reduced hospital costs.
With over 125,000 extremely premature infants benefiting worldwide from Prolacta's human milk-based products, the importance of providing specialized nutrition tailored to this vulnerable population cannot be emphasized enough. Operating the world’s first pharmaceutical-grade processing facilities, Prolacta maintains the highest quality and safety standards in terms of product development, ensuring that every batch is rigorously tested for pathogens and drug traces. This dedication has established Prolacta as a leader in neonatal care, continuously promoting the advancement of human milk nutrition.
As Prolacta Bioscience approaches this remarkable 20-year milestone, the message remains clear: human milk nutrition is invaluable for the health and development of premature infants. The journey continues, and with it, the hope for countless more infants who depend on these life-saving solutions.
The importance of this transition cannot be overstated, especially considering that multiple peer-reviewed studies over the years have confirmed the health risks associated with cow milk for infants born at a very low birth weight. For instance, research indicates that for every 10% increase in cow milk protein in an infant's diet, the risk of developing NEC rises substantially, alongside heightened susceptibility to surgical complications and sepsis.
In light of these findings, the introduction of Prolacta's human milk fortifiers has not only been a critical alternative in clinical settings but has also directly contributed to improving health outcomes for infants in neonatal intensive care units (NICUs). Prolacta's products contain 100% breast milk, are free from cow milk, added fats, and sugars, including corn syrup solids, which aids in reducing complications associated with traditional feeding methods.
Scott Elster, CEO of Prolacta, remarked on the company's extensive history and its enduring mission, stating, "Our legacy and continued mission reflect the vital role of human milk nutrition in helping extremely premature infants not just survive their earliest days but also grow and develop so they can thrive throughout their lives."
Notably, Prolacta's advancements in neonatal nutrition have led to several significant milestones over the years, including:
- - The establishment of a standardized pasteurized donor human milk product, Prolact HM®, in 2007, and the international expansion of its sales into Europe the same year.
- - The introduction of Prolact RTF™, the first ready-to-feed infant formula made exclusively from human milk, in 2013.
- - The release of Surgifort®, the only FDA-approved human milk-based fortifier for term infants recovering from surgery, in 2025.
Prolacta's commitment to clinical efficacy has garnered substantial evidence favoring the nutritional superiority of its products. Studies consistently show that an exclusive human milk diet significantly lowers mortality rates, reduces the incidence of NEC, minimizes feeding intolerance, and improves overall growth, thereby leading to shorter NICU stays and reduced hospital costs.
With over 125,000 extremely premature infants benefiting worldwide from Prolacta's human milk-based products, the importance of providing specialized nutrition tailored to this vulnerable population cannot be emphasized enough. Operating the world’s first pharmaceutical-grade processing facilities, Prolacta maintains the highest quality and safety standards in terms of product development, ensuring that every batch is rigorously tested for pathogens and drug traces. This dedication has established Prolacta as a leader in neonatal care, continuously promoting the advancement of human milk nutrition.
As Prolacta Bioscience approaches this remarkable 20-year milestone, the message remains clear: human milk nutrition is invaluable for the health and development of premature infants. The journey continues, and with it, the hope for countless more infants who depend on these life-saving solutions.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.